41 related articles for article (PubMed ID: 30554838)
1. An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records.
Wysham CH; Lefebvre P; Pilon D; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Duh MS; Ingham M
J Diabetes Complications; 2019 Feb; 33(2):140-147. PubMed ID: 30554838
[TBL] [Abstract][Full Text] [Related]
2. Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors.
Wysham CH; Lefebvre P; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Chow W; Pfeifer M; Duh MS
BMC Endocr Disord; 2017 Jun; 17(1):32. PubMed ID: 28595617
[TBL] [Abstract][Full Text] [Related]
3. Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis.
Buysman EK; Chow W; Henk HJ; Rupnow MF
BMC Endocr Disord; 2015 Nov; 15():67. PubMed ID: 26527413
[TBL] [Abstract][Full Text] [Related]
4. CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice.
Woo V; Bell A; Clement M; Noronha L; Tsoukas MA; Camacho F; Traina S; Georgijev N; Culham MD; Rose JB; Rapattoni W; Bajaj HS
Diabetes Obes Metab; 2019 Mar; 21(3):691-699. PubMed ID: 30393961
[TBL] [Abstract][Full Text] [Related]
5. Effect of Canagliflozin Compared With Sitagliptin on Serum Lipids in Patients with Type 2 Diabetes Mellitus and Heart Failure with Reduced Ejection Fraction: A Post-Hoc Analysis of the CANA-HF Study.
Dixon DL; Billingsley HE; Canada JM; Trankle CR; Kadariya D; Cooke R; Hart L; Van Tassell B; Abbate A; Carbone S
J Cardiovasc Pharmacol; 2021 Sep; 78(3):407-410. PubMed ID: 34132690
[TBL] [Abstract][Full Text] [Related]
6. Predictors of treatment response to liraglutide in type 2 diabetes in a real-world setting.
Simioni N; Berra C; Boemi M; Bossi AC; Candido R; Di Cianni G; Frontoni S; Genovese S; Ponzani P; Provenzano V; Russo GT; Sciangula L; Lapolla A; Bette C; Rossi MC;
Acta Diabetol; 2018 Jun; 55(6):557-568. PubMed ID: 29527621
[TBL] [Abstract][Full Text] [Related]
7. Impact of adherence and weight loss on glycemic control in patients with type 2 diabetes: cohort analyses of integrated medical record, pharmacy claims, and patient-reported data.
McAdam-Marx C; Bellows BK; Unni S; Wygant G; Mukherjee J; Ye X; Brixner DI
J Manag Care Spec Pharm; 2014 Jul; 20(7):691-700. PubMed ID: 24967522
[TBL] [Abstract][Full Text] [Related]
8. Impact of Canagliflozin Treatment on Health-Related Quality of Life among People with Type 2 Diabetes Mellitus: A Pooled Analysis of Patient-Reported Outcomes from Randomized Controlled Trials.
Cai J; Delahanty LM; Akapame S; Slee A; Traina S
Patient; 2018 Jun; 11(3):341-352. PubMed ID: 29313267
[TBL] [Abstract][Full Text] [Related]
9. HbA1c overtesting and overtreatment among US adults with controlled type 2 diabetes, 2001-13: observational population based study.
McCoy RG; Van Houten HK; Ross JS; Montori VM; Shah ND
BMJ; 2015 Dec; 351():h6138. PubMed ID: 26646052
[TBL] [Abstract][Full Text] [Related]
10. Canagliflozin versus placebo for post-bariatric surgery patients with persistent type II diabetes: A randomized controlled trial (CARAT).
Kheniser K; Kashyap SR
Diabetes Obes Metab; 2017 Apr; 19(4):609-610. PubMed ID: 27995724
[No Abstract] [Full Text] [Related]
11. Patient preference for second- and third-line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study.
Shields BM; Angwin CD; Shepherd MH; Britten N; Jones AG; Sattar N; Holman R; Pearson ER; Hattersley AT
Nat Med; 2023 Feb; 29(2):384-391. PubMed ID: 36477734
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective effects of Canagliflozin: Lessons from aged genetically diverse UM-HET3 mice.
Jayarathne HSM; Debarba LK; Jaboro JJ; Ginsburg BC; Miller RA; Sadagurski M
Aging Cell; 2022 Jul; 21(7):e13653. PubMed ID: 35707855
[TBL] [Abstract][Full Text] [Related]
13. Glycemic control associated with secure patient-provider messaging within a shared electronic medical record: a longitudinal analysis.
Harris LT; Koepsell TD; Haneuse SJ; Martin DP; Ralston JD
Diabetes Care; 2013 Sep; 36(9):2726-33. PubMed ID: 23628618
[TBL] [Abstract][Full Text] [Related]
14. Trends and Predictors of Glycemic Control Among Adults With Type 2 Diabetes Covered by Alabama Medicaid, 2011-2019.
Presley CA; Khodneva Y; Juarez LD; Howell CR; Agne AA; Riggs KR; Huang L; Pisu M; Levitan EB; Cherrington AL
Prev Chronic Dis; 2023 Sep; 20():E81. PubMed ID: 37708338
[TBL] [Abstract][Full Text] [Related]
15. Untreated substance use disorder affects glycemic control: Results in patients with type 2 diabetes served within a network of community-based healthcare centers in Florida.
Horigian VE; Schmidt RD; Duan R; Parras D; Chung-Bridges K; Batycki JN; Espinoza K; Taghioff P; Gonzalez S; Davis C; Feaster DJ
Front Public Health; 2023; 11():1122455. PubMed ID: 37006591
[TBL] [Abstract][Full Text] [Related]
16. Glycemic Control and Obesity Among People With Type 2 Diabetes in Europe and Australia: A Retrospective Cohort Analysis.
Newson RS; Divino V; Boye KS; Chen J; DeKoven M; Vallarino C; Ranta K; Mount JE
Diabetes Ther; 2024 Jun; 15(6):1435-1449. PubMed ID: 38683494
[TBL] [Abstract][Full Text] [Related]
17. Impact of Weight Change on Glycemic Control and Metabolic Parameters in T2D: A Retrospective US Study Based on Real-World Data.
Shinde S; Thieu VT; Kwan AYM; Houghton K; Meyers J; Schapiro D
Diabetes Ther; 2024 Feb; 15(2):409-426. PubMed ID: 38038898
[TBL] [Abstract][Full Text] [Related]
18. Canagliflozin retards age-related lesions in heart, kidney, liver, and adrenal gland in genetically heterogenous male mice.
Snyder JM; Casey KM; Galecki A; Harrison DE; Jayarathne H; Kumar N; Macchiarini F; Rosenthal N; Sadagurski M; Salmon AB; Strong R; Miller RA; Ladiges W
Geroscience; 2023 Feb; 45(1):385-397. PubMed ID: 35974129
[TBL] [Abstract][Full Text] [Related]
19. Effect of sitagliptin therapy on IL-29 and its associated signaling molecules in patients with type 2 diabetes mellitus.
Nabiyi S; Sajedi F; Zamani A; Behzad M
Hum Immunol; 2024 Jun; 85(4):110833. PubMed ID: 38897073
[TBL] [Abstract][Full Text] [Related]
20. Assessing the Collective Population Representativeness of Related Type 2 Diabetes Trials by Combining Public Data from ClinicalTrials.gov and NHANES.
He Z; Wang S; Borhanian E; Weng C
Stud Health Technol Inform; 2015; 216():569-73. PubMed ID: 26262115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
